360 related articles for article (PubMed ID: 32934797)
1. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas.
Foster C; Kuruvilla J
F1000Res; 2020; 9():. PubMed ID: 32934797
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic advancements in peripheral T-cell lymphoma.
Reddy NM; Evens AM
Semin Hematol; 2014 Jan; 51(1):17-24. PubMed ID: 24468312
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray.
Lunning MA
Oncology (Williston Park); 2015 Aug; 29(8):545-50. PubMed ID: 26281838
[TBL] [Abstract][Full Text] [Related]
5. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
Lunning MA; Horwitz S
Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
[TBL] [Abstract][Full Text] [Related]
6. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.
Horwitz SM; Zelenetz AD; Gordon LI; Wierda WG; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Fayad LE; Fisher RI; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Hoppe RT; Kaminski MS; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Lunning M; Nademanee A; Press O; Rabinovitch R; Reddy N; Reid E; Roberts K; Saad AA; Sokol L; Swinnen LJ; Vose JM; Yahalom J; Zafar N; Dwyer M; Sundar H; Porcu P
J Natl Compr Canc Netw; 2016 Sep; 14(9):1067-79. PubMed ID: 27587620
[TBL] [Abstract][Full Text] [Related]
7. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
[TBL] [Abstract][Full Text] [Related]
8. Management of Peripheral T-cell Lymphomas and the Role of Transplant.
Foley NC; Mehta-Shah N
Curr Oncol Rep; 2022 Nov; 24(11):1489-1499. PubMed ID: 35947286
[TBL] [Abstract][Full Text] [Related]
9. Transplantation.
Zain J
Cancer Treat Res; 2019; 176():269-287. PubMed ID: 30596223
[TBL] [Abstract][Full Text] [Related]
10. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C
J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805
[TBL] [Abstract][Full Text] [Related]
12. The role of high-dose therapy in peripheral T-cell lymphomas.
Reimer P; Rüdiger T; Wilhelm M
Clin Lymphoma Myeloma; 2006 Mar; 6(5):373-9. PubMed ID: 16640812
[TBL] [Abstract][Full Text] [Related]
13. Stem cell transplantation for peripheral T-cell lymphomas.
Jantunen E; D'Amore F
Leuk Lymphoma; 2004 Mar; 45(3):441-6. PubMed ID: 15160904
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
16. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
17. Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review.
Yang YT; Tai CJ; Chen C; Wu HC; Mikhaylichenko N; Chiu HT; Chen YY; Hsu YE
PLoS One; 2016; 11(10):e0161811. PubMed ID: 27711130
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cell transplantation in peripheral T-cell lymphomas.
Paolo C; Lucia F; Anna D
Leuk Lymphoma; 2007 Aug; 48(8):1496-501. PubMed ID: 17701579
[TBL] [Abstract][Full Text] [Related]
19. Current Treatment of Peripheral T-cell Lymphoma.
Stuver R; Epstein-Peterson ZD; Johnson WT; Khan N; Lewis N; Moskowitz AJ; Sauter CS; Horwitz S
Oncology (Williston Park); 2022 May; 36(5):293-305. PubMed ID: 35576176
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
